BiotechTube
DB Biotech

DB Biotech

Barcelona, Europe - Other· Est.
dbbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

DB Biotech is a private, revenue-generating antibody developer and manufacturer headquartered in Bratislava, Slovakia, with a commercial presence in Barcelona, Spain. Its core asset is a novel, proprietary in-vitro cloning technology developed over 20 years, which produces rabbit clonal antibodies with monoclonal-like specificity targeting linear epitopes. The company operates on a hybrid business model, selling catalog antibodies directly and through a distributor network while offering custom antibody development and proteomic services. Its long-term vision includes advancing into quantitative diagnostics and potential therapeutic humanized antibodies.

Antibodies

Technology Platform

Proprietary in-vitro cloning technology for producing monospecific rabbit clonal antibodies targeting linear epitopes, yielding high specificity, affinity, and avidity.

Opportunities

Growing demand for high-specificity, reproducible antibodies in research and clinical diagnostics presents a key opportunity.
The proprietary technology platform allows DB Biotech to target the premium segment of this market and offer high-value custom development services.
Long-term opportunities exist in expanding into quantitative diagnostics and exploring therapeutic humanized antibodies.

Risk Factors

Intense competition from large, established reagent companies poses a significant market penetration risk.
The business is heavily reliant on the adoption and continuous superiority of its single proprietary technology platform.
As a smaller private entity, scaling operations and funding ambitious new initiatives in diagnostics/therapeutics may be challenging.

Competitive Landscape

DB Biotech competes in the crowded research antibody market against giants like Abcam, Thermo Fisher, and Merck, as well as numerous specialized players. Its differentiation is based on a unique cloning technology promising superior linear epitope targeting. Competition is based on product performance, validation data, price, and breadth of catalog, areas where a small specialist must execute flawlessly to gain share.

More companies in Biologics / Biosimilars →More companies in Europe - Other →